Medivir Ab Aktie - 0GP7

Rendering Error

Professionelle Tools für Privatanleger.

Premium

Current Price

41,70

Gebot

0,00

Fragen

0,00

Volumen

0,00

0,00 Tagesbereich 0,00

41,70 52-Wochen-Bereich 41,70

Marktkapitalisierung

4,677B

Handelsende

41,70

Handelsbeginn

Letzte Trade

(O)

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

884

Ausgegebene Aktien

112.168.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

-37,94

Gewinn pro Aktie (EPS)

-1,1

Erlöse

4,5M

Nettogewinn

-123,3M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Diversified

Website

www.medivir.se

Hauptsitz

Huddinge, Swe

Gegründet

1992

Medivir Ab is listed in the Pharmaceutical Preparations sector of the Londoner Börse with ticker 0GP7. The last closing price for Medivir Ab was SEK41,70. Over the last year, Medivir Ab shares have traded in a share price range of SEK 41,70 to SEK 41,70.

Medivir Ab currently has 112.168.000 shares in issue. The market capitalisation of Medivir Ab is SEK4,68 billion. Medivir Ab has a price to earnings ratio (PE ratio) of -37.94.

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox PR...

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study PR...

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan PR...

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated...

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway PR Newswire STOCKHOLM, Dec. 6, 2023...

Medivir to present at the Carlsquare Equity Research Investor Day

Medivir to present at the Carlsquare Equity Research Investor Day PR Newswire STOCKHOLM, Dec. 6, 2023 STOCKHOLM, Dec. 6, 2023 /PRNewswire/...

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Bulletin from Extraordinary General Meeting in Medivir AB (publ) PR Newswire STOCKHOLM, Dec. 1, 2023 STOCKHOLM, Dec. 1, 2023 /PRNewswire/...

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC PR...

Medivir to present at the Redeye Life Science Day

Medivir to present at the Redeye Life Science Day PR Newswire STOCKHOLM, Nov. 22, 2023 STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB...

Medivir to present at the Erik Penser Bank Company Event

Medivir to present at the Erik Penser Bank Company Event PR Newswire STOCKHOLM, Nov. 21, 2023 STOCKHOLM, Nov. 21, 2023 /PRNewswire/ -- Medivir AB...

Zeitraum †	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	41.7	41.7	41.7	4000	41.7	DE
4	41.7	41.7	41.7	1000	41.7	DE
12	41.7	41.7	41.7	884	41.7	DE
26	41.7	41.7	41.7	690	41.7	DE
52	41.7	41.7	41.7	343	41.7	DE
156	41.7	41.7	41.7	146	41.7	DE
260	41.7	41.7	41.7	307	41.7	DE

0GP7 - Frequently Asked Questions (FAQ)

What is the current Medivir Ab share price?

The current share price of Medivir Ab is SEK 41,70

How many Medivir Ab shares are in issue?

Medivir Ab has 112.168.000 shares in issue

What is the market cap of Medivir Ab?

The market capitalisation of Medivir Ab is SEK 4,68B

What is the 1 year trading range for Medivir Ab share price?

Medivir Ab has traded in the range of SEK 41,70 to SEK 41,70 during the past year

What is the PE ratio of Medivir Ab?

The price to earnings ratio of Medivir Ab is -37,94

What is the cash to sales ratio of Medivir Ab?

The cash to sales ratio of Medivir Ab is 1,04k

What is the reporting currency for Medivir Ab?

Medivir Ab reports financial results in SEK

What is the latest annual turnover for Medivir Ab?

The latest annual turnover of Medivir Ab is SEK 4,5M

What is the latest annual profit for Medivir Ab?

The latest annual profit of Medivir Ab is SEK -123,3M

What is the registered address of Medivir Ab?

The registered address for Medivir Ab is LUNASTIGEN 5, 2ND FLOOR, PO BOX 1086, HUDDINGE, SE-141 22

What is the Medivir Ab website address?

The website address for Medivir Ab is www.medivir.se

Which industry sector does Medivir Ab operate in?

Medivir Ab operates in the PHARMACEUTICAL DIVERSIFIED sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SCGLSealand Capital Galaxy Limited	1,00p (48,15%)	240,36M
ORCPOracle Power Plc	0,0235p (46,88%)	1,14B
ALGWAlpha Growth Plc	0,65p (36,84%)	7,62M
GROCGreenroc Strategic Materials Plc	1,55p (24,00%)	28,38M
AFPAfrican Pioneer Plc	1,10p (22,22%)	4,3M
ELEGElectric Guitar Plc	0,05p (-77,27%)	2,68M
PIERBrighton Pier Group Plc (the)	6,75p (-60,64%)	736,19k
STGStrip Tinning Holdings Plc	24,00p (-22,58%)	135,48k
CPAICapai Plc	0,325p (-18,75%)	368,68M
AFRNAferian Plc	2,50p (-16,67%)	67,67k
PREMPremier African Minerals Limited	0,0335p (4,69%)	2,1B
ORCPOracle Power Plc	0,0235p (46,88%)	1,14B
BZTBezant Resources Plc	0,0265p (8,16%)	637,7M
SYMESupply@me Capital Plc	0,003p (0,00%)	428,79M
CPAICapai Plc	0,325p (-18,75%)	368,68M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Medivir Ab (0GP7)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Medivir Ab

0GP7 Neueste Nachrichten

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

Medivir to present at the Carlsquare Equity Research Investor Day

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Medivir to present at the Redeye Life Science Day

Medivir to present at the Erik Penser Bank Company Event

0GP7 - Frequently Asked Questions (FAQ)

Beweger

0GP7 Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Medivir Ab (0GP7) Börsenkurse

Medivir Ab (0GP7)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Medivir Ab

0GP7 Neueste Nachrichten

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

Medivir to present at the Carlsquare Equity Research Investor Day

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Medivir to present at the Redeye Life Science Day

Medivir to present at the Erik Penser Bank Company Event

0GP7 - Frequently Asked Questions (FAQ)

Beweger

0GP7 Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen